| __timestamp | ACADIA Pharmaceuticals Inc. | Arrowhead Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 32748000 | 24419536 |
| Thursday, January 1, 2015 | 90804000 | 34718089 |
| Friday, January 1, 2016 | 186456000 | 40998209 |
| Sunday, January 1, 2017 | 255062000 | 32022880 |
| Monday, January 1, 2018 | 265758000 | 19110051 |
| Tuesday, January 1, 2019 | 325638000 | 26556257 |
| Wednesday, January 1, 2020 | 388661000 | 52275890 |
| Friday, January 1, 2021 | 396028000 | 80981000 |
| Saturday, January 1, 2022 | 369090000 | 124431000 |
| Sunday, January 1, 2023 | 402466000 | 90932000 |
| Monday, January 1, 2024 | 98761000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, ACADIA Pharmaceuticals Inc. and Arrowhead Pharmaceuticals, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, ACADIA's SG&A expenses surged by over 1,100%, peaking at approximately $402 million in 2023. In contrast, Arrowhead's expenses grew more modestly, increasing by around 270% to nearly $91 million in the same period.
While ACADIA's aggressive spending might indicate a robust expansion strategy, Arrowhead's more conservative approach suggests a focus on cost efficiency. Notably, Arrowhead's expenses in 2022 were just 25% of ACADIA's, highlighting a stark difference in financial strategies. As we look to the future, the missing data for 2024 leaves room for speculation on how these companies will continue to navigate their financial landscapes.
Comparing SG&A Expenses: Genmab A/S vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and ACADIA Pharmaceuticals Inc.
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Arrowhead Pharmaceuticals, Inc.
CymaBay Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and ACADIA Pharmaceuticals Inc.
Comparing SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Arrowhead Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and Evotec SE